Bank of New York Mellon Corp increased its holdings in shares of Athersys, Inc. (NASDAQ:ATHX) by 69.4% during the second quarter, Holdings Channel reports. The fund owned 677,555 shares of the biopharmaceutical company’s stock after purchasing an additional 277,526 shares during the period. Bank of New York Mellon Corp’s holdings in Athersys were worth $1,870,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. bought a new position in Athersys in the 2nd quarter valued at $29,000. Jag Capital Management LLC bought a new position in Athersys in the 2nd quarter valued at $29,000. Emerald Investment Partners LLC bought a new position in Athersys in the 1st quarter valued at $37,000. Ameritas Investment Partners Inc. boosted its position in Athersys by 36.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 15,321 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 4,087 shares during the last quarter. Finally, Nwam LLC bought a new position in Athersys in the 2nd quarter valued at $55,000. Hedge funds and other institutional investors own 28.14% of the company’s stock.

In related news, COO William Lehmann, Jr. sold 20,000 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $2.04, for a total transaction of $40,800.00. Following the sale, the chief operating officer now owns 510,525 shares of the company’s stock, valued at approximately $1,041,471. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.60% of the company’s stock.

A number of brokerages have commented on ATHX. Zacks Investment Research upgraded Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, September 1st. BidaskClub lowered Athersys from a “hold” rating to a “sell” rating in a research report on Monday, August 24th. ValuEngine upgraded Athersys from a “hold” rating to a “buy” rating in a research report on Monday, June 1st. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Athersys in a research report on Tuesday, August 11th. Finally, Bank of America started coverage on Athersys in a research report on Thursday, June 25th. They issued a “buy” rating and a $5.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Athersys currently has a consensus rating of “Buy” and an average price target of $9.00.

Shares of Athersys stock opened at $2.04 on Monday. The company has a market capitalization of $402.70 million, a PE ratio of -6.00 and a beta of -1.80. Athersys, Inc. has a 12 month low of $1.13 and a 12 month high of $4.38. The stock’s fifty day simple moving average is $2.21 and its 200 day simple moving average is $2.50.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.02). The company had revenue of $0.08 million during the quarter. Equities research analysts predict that Athersys, Inc. will post -0.34 EPS for the current fiscal year.

Athersys Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Further Reading: Why is the LIBOR significant?

Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.